Amylyx Pharmaceuticals (AMLX) Return on Capital Employed (QoQ) (2022 - 2026)
Amylyx Pharmaceuticals (AMLX) Return on Capital Employed (QoQ) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Amylyx Pharmaceuticals | 4.34 Bn | 4.34 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -925.00 |
| Mar 31, 2026 | -643.00 |
| Dec 31, 2025 | 1,505.00 |
| Sep 30, 2025 | 4,384.00 |
| Jun 30, 2025 | 1,602.00 |
| Mar 31, 2025 | 4,034.00 |
| Dec 31, 2024 | -4,785.00 |
| Sep 30, 2024 | -5,624.00 |
| Jun 30, 2024 | -3,671.00 |
| Mar 31, 2024 | -3,109.00 |
| Dec 31, 2023 | 1,133.00 |
| Sep 30, 2023 | 2,026.00 |
| Jun 30, 2023 | 2,257.00 |
| Mar 31, 2023 | 3,925.00 |
| Dec 31, 2022 | 2,447.00 |
| Sep 30, 2022 | -3,957.00 |
| Jun 30, 2022 | 363.00 |